CNTX-0290

A bruised Eli Lilly buys rights to Centrexion’s early-stage pain drug for $47.5M upfront
Endpoints
Tue, 05/28/19 - 10:09 am
Eli Lilly
non-opioid pain treatments
Centrexion
CNTX-0290